Title of article - Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.
Abstract
Malignant pericardial effusion (MPCE) is a common complication of advanced malignant tumors, and interferes severely with patient prognosis and quality of life. The standard treatment for this complication is intracavitary perfusion of chemotherapeutic drugs, which is limited by unsatisfactory therapeutic effects and serious adverse events. We report a patient with MPCE who was treated with bevacizumab by pericardial perfusion, resulting in a complete response. This case supports the use of intrapericardial bevacizumab as a potential treatment for MPCE.
CLICK HERE for Full article Click button above to go to original article link with complete article details for Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.
Please CLICK HERE to discuss with us on facebook about this article.
Click below for Details of research Institute
Weifang Medical University, Weifang, People's Republic of China ; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People's Republic of China.
Details of Journal for Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.
Journal Title - OncoTargets and therapy
ISSN - 1178-6930
Volume - 8
Issue - 0
Publish date - 2015-
Language - eng
Country - New Zealand
No comments:
Post a Comment